FDA Resumes Testing of Anti-NFG Drugs

The Food and Drug Administration recently voted to allow testing to resume for an experimental class of pain medications used to treat osteoarthritis.

According to MSNBC, the FDA previously stopped testing of anti-nerve growth factor (anti-NGF) drugs in 2010 and early 2011 because some patients taking them reported deterioration of their joints and required joint replacement surgeries. The agency cited the need for new pain drugs for patients who do not benefit from current medications as a contributing factor in their choice to resume testing of the drug.

Johnson & Johnson, Pfizer, and Regeneration Pharmaceuticals were the three drug companies testing anti-NGF medications, such as tanezumab, prior to the cessation of the trials.

If you or a loved one were harmed by a dangerous drug, contact Sokolove Law for a free legal consultation and to find out if a dangerous drug lawyer may be able to help you.